These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 20363366

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
    [Abstract] [Full Text] [Related]

  • 3. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun 19; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 9. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
    Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ.
    Aliment Pharmacol Ther; 2011 Jan 19; 33(2):185-93. PubMed ID: 21083671
    [Abstract] [Full Text] [Related]

  • 10. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.
    Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P.
    Clin Gastroenterol Hepatol; 2010 Apr 19; 8(4):357-63. PubMed ID: 20096379
    [Abstract] [Full Text] [Related]

  • 13. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb 19; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 14. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
    Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P.
    Clin Gastroenterol Hepatol; 2010 Aug 19; 8(8):688-695.e2. PubMed ID: 20451663
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR.
    Clin Gastroenterol Hepatol; 2011 Aug 15; 9(8):670-678.e3. PubMed ID: 21642014
    [Abstract] [Full Text] [Related]

  • 18. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
    Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.
    Am J Gastroenterol; 2009 Aug 15; 104(8):1976-83. PubMed ID: 19471252
    [Abstract] [Full Text] [Related]

  • 19. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
    Baker DE.
    Rev Gastroenterol Disord; 2008 Aug 15; 8(4):240-53. PubMed ID: 19107098
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
    Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR.
    Aliment Pharmacol Ther; 2014 Oct 15; 40(8):903-16. PubMed ID: 25146586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.